Registry Guidance Sought Following HHS Privacy Rule Implementation
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers seeking protected health information (PHI) from covered entities for postmarket surveillance will need to take precautions to ensure their studies are subject to FDA oversight, and thereby exempted from HHS' privacy rule.
You may also be interested in...
Privacy Bills Should Focus On Compliance Date, Preemption, Lobbyist Says
Medical privacy legislation should focus on rolling back the compliance date of the HHS regulations and granting federal preemption of state privacy laws rather than addressing details of the regs, Healthcare Leadership Council Executive VP Alan Mertz said.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.